7 stories found
Several publicly traded biotechnology and healthcare companies have disclosed new equity awards designed to attract and retain key personnel. These filings comply with Nasdaq Listing Rule 5635(c)(4), which permits such inducement grants outside standard executive compensation plans.
Edgewise Therapeutics, Inc. (EWTX) has had its price target raised to $59 by analysts following positive data from its HCM (Hypertrophic Cardiomyopathy) trial.
Edgewise Therapeutics stock experienced significant gains, topping the market on Tuesday due to undisclosed factors driving its strong performance.
Edgewise Therapeutics announced its GAAP Earnings Per Share (EPS) for the latest period, reporting a loss of $0.53 per share.
Several companies across various sectors have released their financial forecasts and guidance for 2026. These projections detail expected revenues, adjusted EBITDA, and other key performance metrics for the upcoming fiscal year.
An analysis explores whether Edgewise Therapeutics, Inc. (EWTX) represents a favorable investment opportunity in the current market.
Canaccord has raised its price target for Wave Life Sciences Ltd. (WVE) to $52 following a comprehensive review of the company's pipeline.